Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Average Rating of "Hold" from Brokerages

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) has earned a consensus recommendation of "Hold" from the nine brokerages that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $45.00.

Several research analysts have commented on IART shares. StockNews.com raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Thursday. Wells Fargo & Company raised Integra LifeSciences from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $40.00 to $49.00 in a research report on Tuesday, December 5th. JMP Securities cut their price target on Integra LifeSciences from $55.00 to $49.00 and set a "market outperform" rating on the stock in a research report on Thursday, February 29th. Finally, Truist Financial cut their price target on Integra LifeSciences from $46.00 to $41.00 and set a "hold" rating for the company in a research note on Friday, March 1st.

Integra LifeSciences Price Performance

IART stock traded down $0.73 during midday trading on Monday, reaching $34.72. The stock had a trading volume of 853,413 shares, compared to its average volume of 657,086. The company's fifty day simple moving average is $39.35 and its 200 day simple moving average is $39.68. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. The company has a market cap of $2.73 billion, a price-to-earnings ratio of 42.71, a price-to-earnings-growth ratio of 1.07 and a beta of 1.12. Integra LifeSciences has a 52-week low of $33.24 and a 52-week high of $59.33.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.90 by ($0.01). The company had revenue of $397.00 million during the quarter, compared to analyst estimates of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm's revenue was down .3% compared to the same quarter last year. During the same period last year, the business earned $0.94 earnings per share. As a group, sell-side analysts predict that Integra LifeSciences will post 3.19 earnings per share for the current fiscal year.

Institutional Trading of Integra LifeSciences

Large investors have recently made changes to their positions in the stock. Swiss National Bank boosted its stake in Integra LifeSciences by 0.9% in the 3rd quarter. Swiss National Bank now owns 161,994 shares of the life sciences company's stock worth $6,187,000 after buying an additional 1,500 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new position in shares of Integra LifeSciences in the 3rd quarter valued at about $43,034,000. Bridgefront Capital LLC lifted its stake in shares of Integra LifeSciences by 299.3% in the 2nd quarter. Bridgefront Capital LLC now owns 16,348 shares of the life sciences company's stock valued at $672,000 after purchasing an additional 12,254 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Integra LifeSciences in the 3rd quarter valued at about $25,443,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Integra LifeSciences by 451.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 70,827 shares of the life sciences company's stock valued at $2,705,000 after purchasing an additional 57,993 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.